TheEdgeResearch
Home / Stocks / UPXI

Upexi, Inc. (UPXI)

NASDAQ Consumer Defensive Household & Personal Products
$0.83 ▲ +3.27%
Market Cap
$60.9M
Sector
Consumer Defensive
Industry
Household & Personal Products
Beta
-0.24
52-Wk Range
0.54-9.115
CEO
Allan Marshall
Country
US
Currency
USD

Upexi, Inc. operates in the Household & Personal Products industry of the Consumer Defensive sector, headquartered in Tampa, FL, US. The stock last traded at $0.83, up 3.27% on the session, giving a market capitalisation of $60.9M. On trailing twelve-month figures it carries a trailing P/E of -0.23, a net margin of -874.0%. Its beta of -0.24 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.23
Price / Sales
2.33
Price / Book
-1.05
EV / EBITDA
-1.38
Gross margin
86.0%
Operating margin
182.6%
Net margin
-874.0%
Return on equity
Debt / equity
-4.68
Current ratio
1.72
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
59
IPO date
2021-06-23
Headquarters
Tampa, FL, US
About Upexi, Inc.

Upexi, Inc. engages in the development, manufacture, and distribution of consumer products. It offers nail grinder and healthy all-natural pet supplements under the LuckyTail brand; energy solutions under the PRAX brand; functional mushrooms under the Cure Mushrooms brand; cannabinoid under the Moonwlkr brand; and gummies and other products under the Gumi Labs brand name. The company sells its products through direct-to-consumer network, wholesale partnerships, and third-party platform. It also focuses on cryptocurrency industry and management of cash assets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. Upexi, Inc. was incorporated in 2018 and is headquartered in Tampa, Florida.

Comparable companies

Upexi, Inc. is most often compared with the following Consumer Defensive names:

ARENATNICURICXDOEVCRDCMSSPSTRZTRUETRVG
More research on UPXI
UPXI technical analysis UPXI TheEdge Score Compare against peers
Open full interactive analysis & DCF →